No Data
No Data
Shanxi Zhendong Pharmaceutical: Summary of Half-Year Report in 2024.
Shanxi Zhendong Pharmaceutical: Half-year report for the year 2024.
Shanxi Zhendong Pharmaceutical (300158.SZ): Non-specific antiviral drugs for monkeypox.
Shanxi Zhendong Pharmaceutical (300158.SZ) stated on the investor communication platform on August 20 that the company's pharmaceuticals including Qingwen Jiedu Pills, Ibuprofen Tablets, Acetaminophen Tablets, Yinqiao Jiedu Pills, Fangfeng Tongsheng Pills, and Huoxiang Zhengqi Capsules can be used to treat or alleviate symptoms of COVID-19. The company does not have any specific antiviral drugs for monkeypox.
Shanxi Zhendong pharmaceutical (300158.SZ): Currently no research and development of ADC drugs.
Shanxi Zhendong Pharmaceutical (300158.SZ) stated on its investor platform that the company is currently not developing ADC drugs. The company primarily engages in the development of innovative drugs, generic drugs, and modern traditional Chinese medicine, and is dedicated to the research and development of pipeline medicines for cancer, dermatology, urology, cardiovascular and cerebrovascular diseases.
Shanxi Zhendong Pharmaceutical (300158.SZ): Gross margin of traditional chinese medicine materials has remained stable.
Shanxi Zhendong Pharmaceutical (300158.SZ) stated on the investor interaction platform on August 12th that the company operates various traditional Chinese medicine varieties. Although some traditional Chinese medicine prices have risen sharply, the impact on the overall profitability of the traditional Chinese medicine business is relatively small. Overall, the gross margin of traditional Chinese medicine is basically stable.
Little Excitement Around Shanxi Zhendong Pharmaceutical Co.,Ltd's (SZSE:300158) Revenues
No Data